Big Pharma balks at lawsuit rule

Fighting lawsuits is bad enough. After all, the pharma business is full of them: patent fights, product liability cases, regulatory disputes. Now, the Financial Accounting Standards Board--the accounting organization that sets the rules for companies' numbers-reporting--wants businesses to regularly disclose how much various lawsuits will cost them. Six Big Pharma companies--Johnson & Johnson, Novartis, Pfizer, Merck, Eli Lilly, and Wyeth--weighed in with a protest.

Estimating those costs is well nigh impossible, not to mention expensive, the companies contended in a letter to FASB. Examples? Take the fight over Merck's painkiller Vioxx. First, a Texas jury awarded one survivor more than $250 million, then a court struck the ruling down completely. Wyeth's fen-phen troubles are also an example. The company thought it might settle those claims for $3.75 billion, but instead has set aside or paid out more than $21 billion in legal fees, judgments and settlements. With numbers all over the map like that, how could estimates be valuable to investors, they argue. A former FASB chairman agrees; he told the Wall Street Journal, "I think the board has gone too far."

- read the WSJ story

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.